InsightAce Analytic Pvt. Ltd. has announced the release of a market assessment report on “Global AI Oncology Market – (By Cancer Types (Solid Malignancies, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumors, Others), By End Users (Hospitals, Pharmaceutical Companies, Research Institutes, Others)), By Regions, Trends, Industry Competitive Analysis, Revenue And Forecast To 2035”.
The global oncology AI market size was valued at USD 1.91 billion in 2025 and is projected to reach USD 7.31 billion by 2035, at a CAGR of 14.5% during the forecast period 2026-2035.
Get free access to demo reports, Excel pivots, and a table of contents. https://www.insightaceanalytic.com/request-sample/2529
Artificial intelligence (AI) is reshaping the field of oncology by advancing cancer diagnosis, treatment planning, and patient management through advanced machine learning algorithms and data analysis. By analyzing large and complex medical datasets, AI systems can detect subtle patterns, provide personalized treatment recommendations, support evidence-based clinical decision-making, and improve patient outcomes. Key technologies such as deep learning, natural language processing (NLP), computer vision, and genomics-driven analytics can help improve diagnostic accuracy, optimize treatment strategies, and improve overall healthcare efficiency.
The strategic value of AI in oncology lies in its ability to provide accurate data-driven insights, enabling accurate diagnosis and personalized care tailored to each patient’s clinical profile. AI platforms also facilitate early detection of diseases by evaluating patient data to identify potential risks and support proactive and proactive interventions. Additionally, AI-driven automation will improve operational efficiency, reduce healthcare costs, and streamline clinical workflows, positioning artificial intelligence as a transformative force in oncology and the broader healthcare ecosystem.
List of prominent players in the Oncology AI market:
• Belk
• CancerCenter.AI
• Concert AI
• GE Healthcare
• IBM Watson Health
• iCAD
• JKLK inspection
• Median Technologies
• Path AI
• Roche Diagnostics
Get expertise in one click: https://calendly.com/insightaceanalytic/30min?month=2025-02
Market dynamics: AI in oncology
Market drivers:
The increasing global incidence of cancer, including common types of cancer such as lung, breast, prostate, colorectal, and brain cancers, is a major driver of AI adoption in oncology. According to the American Cancer Society’s 2024 report, the United States is expected to record approximately 234,580 new lung cancer cases and 125,070 related deaths, highlighting the urgent need for advanced oncology solutions.
The World Health Organization (WHO) estimates that approximately 20 million new cancer diagnoses are made annually worldwide, highlighting the need for enhanced diagnostic and treatment approaches. AI-powered precision medicine, which integrates complex genomic datasets, advanced medical imaging, and advanced analytics, plays a critical role in accelerating early cancer detection, optimizing personalized treatment plans, and improving overall patient outcomes.
Market challenges:
Although AI has transformative potential, widespread adoption of AI in oncology faces several obstacles. Interoperability is hampered by limited access to high-quality multi-institutional datasets and inconsistencies in electronic health record (EHR) documentation. The lack of standardized imaging protocols and unified data sharing frameworks further limits clinical application and may impact diagnostic accuracy and treatment efficacy. Labor-intensive processes such as tumor segmentation and annotation also limit scalability. Additionally, successful implementation requires effective collaboration between oncologists, radiologists, and data scientists, creating operational complexity within a multidisciplinary healthcare environment.
Regional trends:
North America currently leads the AI oncology market, supported by robust medical infrastructure, advanced medical imaging capabilities, and a strong research ecosystem. In 2024, approximately 2,001,140 new cancer cases and 611,720 cancer-related deaths are expected to be reported in the United States, reinforcing the critical need for innovative oncology solutions. The region has benefited from significant R&D investments by leading academic and biotech institutions, driving the development of AI-powered oncology applications.
Additionally, a favorable regulatory environment, including supportive reimbursement policies, facilitates rapid adoption of AI solutions in clinical practice. Strong demand for accurate and efficient diagnostic and therapeutic tools continues to strengthen North America’s leadership in AI-driven oncology innovation.
Unleash your GTM strategy: https://www.insightaceanalytic.com/customisation/2529
Recent developments:
• In May 2024, ConcertAI announced CARA AI, an advanced predictive and generative AI suite, at the 2024 ASCO Annual Meeting to provide multimodal data management and facilitate collaborative research efforts from translational to clinical development stages. Additionally, ConcertAI has introduced updates to its SmartLinQ oncology quality management platform, TriaLinQ.
• In May 2024, GE Healthcare will introduce Revolution RT, a new AI-powered oncology solution, ushering in a “new era” in computed tomography (CT) for radiation therapy. Revolution RT features innovative hardware and software that improves image accuracy and streamlines simulation workflows, aiming to personalize and simplify oncology treatment pathways for clinicians and patients. The technology was unveiled at the European Society of Radiation Oncology 2024 Congress in Glasgow, Scotland.
AI segmentation in the oncology market –
By type of cancer
• Solid malignant tumor
• Breast cancer
• Lung cancer
• Prostate cancer
• Colorectal cancer
• Brain tumor
• others
By end user
• hospital
・Pharmaceutical companies
• Research institute
• others
By region-
North America-
• US
• Canada
• Mexico
Europe-
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
Asia Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
latin america-
• Brazil
• Argentina
• Rest of Latin America
Middle East and Africa –
• GCC countries
• South Africa
• Rest of the Middle East and Africa
Read the summary report – https://www.insightaceanalytic.com/report/ai-in-oncology-market-/2529
About us:
InsightAce Analytic is a market research and consulting firm that helps clients make strategic decisions. Our qualitative and quantitative market intelligence solutions inform your need for market and competitive intelligence to grow your business. We help our clients gain competitive advantage by identifying untapped markets, exploring new competitive technologies, segmenting potential markets, and repositioning products. Our expertise lies in providing syndicated and custom market intelligence reports with in-depth analysis including key market insights in a timely and cost-effective manner.
inquiry:
InsightAce Analytic Pvt. Ltd.
visit: https://www.insightaceanalytic.com/
Phone number: +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
This release was published on openPR.